Invivyd, Inc. Reports Positive In Vitro Neutralization Data for PEMGARDA™ Against Dominant SARS-CoV-2 Variant LP.8.1 March 05, 2025 — 07:11 am EST Written by None for Quiver Quantitative -> ...

Invivyd, Inc., a biopharmaceutical company focused on developing treatments for serious viral infectious diseases, has announced a conference call on May 15, 2025, at 8:30 a.m. ET to discuss its ...

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2.

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group ...

Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study ...

Invivyd, Inc. (NASDAQ:IVVD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ETCompany ParticipantsKatie Falzone - VP, Corporate ControllerMarc Elia ...

On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue ...

Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ETCorporate ParticipantsScott Young - SVP, Investor Relations and ...

LOS ANGELES, CA / ACCESSWIRE / March 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio ...

View the latest Invivyd Inc. (IVVD) stock price, news, historical charts, analyst ratings and financial information from WSJ.